Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
Silo Pharma filed a provisional patent application for ibogaine-based therapeutics targeting traumatic brain injury (TBI) and associated neuropsychiatric conditions. The initiative aligns with a recent federal Executive Order to accelerate psychedelic medicine innovation, targeting a market estimated to reach $6 billion by 2032.
Key figures
- Tbi c AGR 2025 2032
- 6.0%
- Tbi market size 2032
- $6.0 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.